AZN Latest Headlines

Tozorakimab Achieves Key Phase III Goal, Offering Hope for COPD Patients Resistant to Standard Therapies

Market Chameleon (Mon, 20-Apr 7:31 AM)

Astra posts another late-stage trial win for COPD therapy

at seekingalpha.com (Mon, 20-Apr 8:35 AM)

AstraZeneca’s Tozorakimab Delivers Third Positive Phase III Result in COPD

at www.tipranks.com (Mon, 20-Apr 2:14 AM)

Compass Pathways Cheers Trump Order To Accelerate Access To Psychedlic Drug Treatements: 'Recognizes Profound Urgency Of Mental Health Crisis'

at www.benzinga.com (Sun, 19-Apr 3:55 AM)

Trump Accelerates Psychedelic Research With $50 Million Ibogaine Commitment

at www.benzinga.com (Sat, 18-Apr 3:46 PM)

Trump nominates Erica Schwartz to lead CDC, ending months-long search

at seekingalpha.com (Fri, 17-Apr 3:28 AM)

AstraZeneca Nears Key COPD Milestone With Phase III Tozorakimab Trial

at www.tipranks.com (Thu, 16-Apr 12:30 PM)

AstraZeneca’s OBERON COPD Trial Reaches Completion, Setting Up a Key Catalyst for AZN

at www.tipranks.com (Thu, 16-Apr 12:30 PM)

White House reportedly eyeing former deputy surgeon general to lead CDC

at seekingalpha.com (Wed, 15-Apr 7:20 AM)

AstraZeneca’s Combo Therapy With IMFINZI, IMJUDO, and Lenvatinib Delivers Meaningful Progression-Free Survival Gains in Early Liver Cancer

Market Chameleon (Thu, 2-Apr 7:11 AM)

Tozorakimab Delivers Clinically Meaningful Results in Two Phase III COPD Trials: AstraZeneca Expands Biologic Leadership

Market Chameleon (Fri, 27-Mar 7:06 AM)

ENHERTU’s Priority Review May Reshape HER2-Positive Breast Cancer Care With 53% Reduction in Recurrence Risk

Market Chameleon (Mon, 9-Mar 7:07 AM)

AstraZeneca’s 2025 Results Highlight Strong Revenue Growth, Robust Pipeline, and Global Expansion Moves

Market Chameleon (Tue, 10-Feb 7:13 AM)